259 related articles for article (PubMed ID: 33627312)
1. Effect of screening by clinical breast examination on breast cancer incidence and mortality after 20 years: prospective, cluster randomised controlled trial in Mumbai.
Mittra I; Mishra GA; Dikshit RP; Gupta S; Kulkarni VY; Shaikh HKA; Shastri SS; Hawaldar R; Gupta S; Pramesh CS; Badwe RA
BMJ; 2021 Feb; 372():n256. PubMed ID: 33627312
[TBL] [Abstract][Full Text] [Related]
2. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial.
Miller AB; Wall C; Baines CJ; Sun P; To T; Narod SA
BMJ; 2014 Feb; 348():g366. PubMed ID: 24519768
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of mammographic surveillance services in women aged 40-49 years with a moderate family history of breast cancer: a single-arm cohort study.
Duffy SW; Mackay J; Thomas S; Anderson E; Chen TH; Ellis I; Evans G; Fielder H; Fox R; Gui G; Macmillan D; Moss S; Rogers C; Sibbering M; Wallis M; Warren R; Watson E; Whynes D; Allgood P; Caunt J
Health Technol Assess; 2013 Mar; 17(11):vii-xiv, 1-95. PubMed ID: 23489892
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of triennial screening with clinical breast examination: 14-years follow-up outcomes of randomized clinical trial in Trivandrum, India.
Ramadas K; Basu P; Mathew BS; Muwonge R; Venugopal M; Prakasan AM; Malu R; Lucas E; Augustine P; Mony RP; Thara S; Sankaranarayanan R
Cancer; 2023 Jan; 129(2):272-282. PubMed ID: 36321193
[TBL] [Abstract][Full Text] [Related]
5. Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study.
FH01 collaborative teams
Lancet Oncol; 2010 Dec; 11(12):1127-34. PubMed ID: 21093374
[TBL] [Abstract][Full Text] [Related]
6. A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: methodology and interim results after three rounds of screening.
Mittra I; Mishra GA; Singh S; Aranke S; Notani P; Badwe R; Miller AB; Daniel EE; Gupta S; Uplap P; Thakur MH; Ramani S; Kerkar R; Ganesh B; Shastri SS
Int J Cancer; 2010 Feb; 126(4):976-84. PubMed ID: 19697326
[TBL] [Abstract][Full Text] [Related]
7. Mammography service screening and breast cancer mortality in New Zealand: a National Cohort Study 1999-2011.
Morrell S; Taylor R; Roder D; Robson B; Gregory M; Craig K
Br J Cancer; 2017 Mar; 116(6):828-839. PubMed ID: 28183141
[TBL] [Abstract][Full Text] [Related]
8. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years.
Miller AB; Baines CJ; To T; Wall C
CMAJ; 1992 Nov; 147(10):1459-76. PubMed ID: 1423087
[TBL] [Abstract][Full Text] [Related]
9. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years.
Miller AB; Baines CJ; To T; Wall C
CMAJ; 1992 Nov; 147(10):1477-88. PubMed ID: 1423088
[TBL] [Abstract][Full Text] [Related]
10. [Tailored Breast Screening Trial (TBST)].
Paci E; Mantellini P; Giorgi Rossi P; Falini P; Puliti D;
Epidemiol Prev; 2013; 37(4-5):317-27. PubMed ID: 24293498
[TBL] [Abstract][Full Text] [Related]
11. Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India.
Shastri SS; Mittra I; Mishra GA; Gupta S; Dikshit R; Singh S; Badwe RA
J Natl Cancer Inst; 2014 Mar; 106(3):dju009. PubMed ID: 24563518
[TBL] [Abstract][Full Text] [Related]
12. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial.
Duffy SW; Vulkan D; Cuckle H; Parmar D; Sheikh S; Smith RA; Evans A; Blyuss O; Johns L; Ellis IO; Myles J; Sasieni PD; Moss SM
Lancet Oncol; 2020 Sep; 21(9):1165-1172. PubMed ID: 32800099
[TBL] [Abstract][Full Text] [Related]
13. MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
Saadatmand S; Geuzinge HA; Rutgers EJT; Mann RM; de Roy van Zuidewijn DBW; Zonderland HM; Tollenaar RAEM; Lobbes MBI; Ausems MGEM; van 't Riet M; Hooning MJ; Mares-Engelberts I; Luiten EJT; Heijnsdijk EAM; Verhoef C; Karssemeijer N; Oosterwijk JC; Obdeijn IM; de Koning HJ; Tilanus-Linthorst MMA;
Lancet Oncol; 2019 Aug; 20(8):1136-1147. PubMed ID: 31221620
[TBL] [Abstract][Full Text] [Related]
14. Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial.
Hofvind S; Holen ÅS; Aase HS; Houssami N; Sebuødegård S; Moger TA; Haldorsen IS; Akslen LA
Lancet Oncol; 2019 Jun; 20(6):795-805. PubMed ID: 31078459
[TBL] [Abstract][Full Text] [Related]
15. Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2007; 7(1):1-32. PubMed ID: 23074501
[TBL] [Abstract][Full Text] [Related]
16. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials.
de Koning HJ; Boer R; Warmerdam PG; Beemsterboer PM; van der Maas PJ
J Natl Cancer Inst; 1995 Aug; 87(16):1217-23. PubMed ID: 7563167
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Mortality Among Participants of Women's Health Initiative Trials With Screening-Detected Breast Cancers vs Interval Breast Cancers.
Irvin VL; Zhang Z; Simon MS; Chlebowski RT; Luoh SW; Shadyab AH; Krok-Schoen JL; Tabung FK; Qi L; Stefanick ML; Schedin P; Jindal S
JAMA Netw Open; 2020 Jun; 3(6):e207227. PubMed ID: 32602908
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]